Tag: core

CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). These latest findings from Part C of the DEVOTE trial evaluating a higher dose regimen of nusinersen and the NURTURE trial which evaluated the approved 12 mg regimen (SPINRAZA^®) in clinically presymptomatic SMA were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif. Biogen’s applications for the higher dose regimen of nusinersen are currently under review in the U.S., Europe, Japan and other global markets. The higher dose regimen of nusinersen comprises a more rapid loading regimen – two 50 mg doses 14 days apart – and a higher maintenance regimen – 28 mg every four months.

Amid industry recognition, XWELL expands its wellness footprint, bringing self-care beyond the terminal with new locations and partnerships

Trading to Commence Under Symbol “BTCT”

Exploring the Growing Demand for Safe, At-Home Workouts That Support Strength, Hormonal Balance, and Longevity in Men Over 50

TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (“BlackRock”) (NYSE:BLK) today announced updates to the investment risk ratings of certain iShares exchange-traded funds (“iShares ETFs”), a reduction to the annual management fees of certain iShares ETFs, and the commencement of securities lending transactions of certain iShares ETFs, as further described below.